Heart failure and sleep-disordered breathing share a bidirectional relationship with meaningful prescribing consequences. A patient with heart failure with reduced ejection fraction (HFrEF, LVEF ≤ 45%) is likely to exhibit some combination of obstructive sleep apnea and Cheyne-Stokes respiration with central sleep apnea. The obstructive piece is treated with CPAP in the usual way. The central piece used to be treated with adaptive servo-ventilation (ASV) — until the SERVE-HF trial in 2015 showed that ASV increased all-cause and cardiovascular mortality in exactly this population. That finding reshaped guideline prescribing, and many Indian clinicians are still working through the implications. This article lays out the current standard of care and the rationale behind it.
Sleep-disordered breathing in heart failure — what you see
Roughly half of HFrEF patients, screened by polysomnography, have clinically significant sleep-disordered breathing. The phenotype is usually mixed:
- Obstructive events driven by upper-airway collapsibility, fluid redistribution in the supine position (a phenomenon called rostral fluid shift), and age-related anatomy. These respond to CPAP.
- Central events in the Cheyne-Stokes respiration pattern — a crescendo-decrescendo waxing-and-waning of tidal volume with central apneas at the troughs, classically with a cycle length of 40–90 seconds. Driven by prolonged circulation time, elevated chemoreflex sensitivity, and pulmonary congestion.
- Mixed events with components of both.
The same physiology exists in HFpEF (preserved ejection fraction) patients, though the weighting tends to be more obstructive and less Cheyne-Stokes than in HFrEF. Indian prevalence data track international figures: in Indian HFrEF cohorts, 40–60% have AHI ≥ 15 on screening sleep studies.
The SERVE-HF finding — why ASV is off the table for HFrEF
Adaptive servo-ventilation is a PAP mode designed specifically for Cheyne-Stokes respiration. It delivers varying pressure support that increases during apneic troughs and decreases during hyperpneic peaks, damping the respiratory oscillation. The clinical logic was good: if the underlying problem is a breathing instability, dampen the instability.
SERVE-HF was a randomised controlled trial of ASV versus usual care in 1,325 HFrEF patients with predominantly central sleep apnea. The primary endpoint was time to composite cardiovascular event. Enrolment ran from 2008 to 2013.
The result, published in 2015, was that ASV produced a statistically significant increase in all-cause and cardiovascular mortality compared to usual care. The hazard ratio was approximately 1.28 for all-cause mortality and 1.34 for cardiovascular mortality. The finding was unexpected and, after regulatory review and guideline re-issue, led to a formal contraindication of ASV in patients with symptomatic HFrEF with LVEF ≤ 45%.
The mechanism is not fully understood. The leading hypothesis is that Cheyne-Stokes respiration in severe HF may be partly protective (the hyperpneic phase assists venous return, and the respiratory cycle may stabilise autonomic tone). Dampening it with ASV removes a compensatory mechanism. The effect is real; the biology is still being worked out. The clinical implication is unambiguous.
What this means in practice:
- Do not use ASV in HFrEF with LVEF ≤ 45%. This applies whether the sleep-disordered breathing is predominantly central or mixed.
- ASV is still appropriate for complex sleep apnea in preserved-LVEF patients, for CPAP-emergent central apnea in non-HF patients, and for some central apnea of non-HF cause.
- Re-evaluate any HFrEF patient already on ASV. Many Indian patients who were started on ASV between 2010 and 2015 are still on it; the conversation to move them off should be happening at each cardiology follow-up.
What to use instead in HFrEF with sleep-disordered breathing
The current prescribing landscape:
CPAP for obstructive predominant pictures
If the patient’s sleep-disordered breathing is primarily obstructive — high proportion of obstructive events, modest central component — CPAP remains the treatment of choice. Standard titration rules apply. Evidence for cardiovascular benefit of CPAP in HF with OSA is modest but supportive: modest improvements in LVEF, blood pressure, and exercise capacity over months of therapy.
CANPAP is worth noting specifically: CPAP in HFrEF with central sleep apnea produced a survival benefit only in the subgroup where central events were suppressed to AHI < 15 on CPAP. In the population where CPAP did not suppress central events, no benefit was seen. This is the origin of the “CPAP first, reassess on therapy” approach that current guidelines suggest for HFrEF with CSA.
Home NIV (BiPAP-ST) for selected patients
For patients whose sleep-disordered breathing is primarily central and does not respond to CPAP, and who are not HFrEF-contraindicated for positive pressure, home non-invasive ventilation in bilevel-ST mode — BiPAP with a backup rate — is an option. The evidence base is smaller than for CPAP, the titration is more complex, and the decision should be made by a sleep physician working with the treating cardiologist.
Home NIV is not a standard-of-care prescription for HF-related central apnea the way CPAP is for OSA. It is a specialist decision in selected patients, usually those with persistent symptomatic nocturnal disturbance despite CPAP and medical optimisation.
Oxygen supplementation
Nocturnal oxygen (typically 2–3 LPM via nasal cannula, set to maintain SpO₂ > 90%) has been used in Cheyne-Stokes respiration to reduce the hypoxic drive contribution to the respiratory oscillation. Published data show modest reduction in AHI and some symptomatic benefit. It does not carry the mortality concern that ASV carries, but it also does not carry the established mortality benefit that optimal HF medical therapy carries.
Optimise heart failure first
Before any PAP or oxygen escalation, the single highest-yield intervention is optimisation of heart failure medical therapy. Contemporary HFrEF management — ARNI/ACE-I/ARB, beta-blocker, MRA, SGLT2 inhibitor, loop diuretic titration, device therapy where indicated — reduces pulmonary congestion, rostral fluid shift, and consequently sleep-disordered breathing severity. In many patients, aggressive HF optimisation meaningfully improves the sleep profile without any positive-pressure intervention.
HFpEF — where OSA is usually the bigger story
HFpEF patients with sleep-disordered breathing show a different phenotype: the OSA component is usually larger and the central component smaller than in HFrEF. CPAP is appropriate and effective. SERVE-HF findings do not apply. ASV can be used for complex sleep apnea in HFpEF, with usual caveats.
The clinically important point for HFpEF: OSA is a major driver of recurrent atrial fibrillation and poorly controlled nocturnal blood pressure in this population. Treatment of OSA is, pragmatically, part of HFpEF management — not a separate conversation. Unfortunately, screening rates in Indian HFpEF clinics remain low, and many patients who would benefit from CPAP are not diagnosed.
Device selection in an Indian context
For HF patients with sleep-disordered breathing in India, device selection should prioritise:
- Proven algorithm and auto-titration quality — CPAP or APAP from a major manufacturer (ResMed AirSense/AirStart series, Philips DreamStation, BMC GII). Cardiopulmonary patients are less forgiving of algorithm misbehaviour than straightforward OSA.
- Leak compensation — HF patients are often on fluid restriction and may have variable edema; mask fit can change over weeks. Devices with strong leak-compensation algorithms (ResMed, Philips) handle this better.
- Telehealth reporting — AirView-equivalent cloud reporting is genuinely useful in HF populations because the treating cardiologist and sleep physician can review objective data without a clinic visit. This matters more in HF than in routine OSA.
- Avoid ASV in HFrEF. This is a non-negotiable. A distributor or sales channel pushing ASV for an HFrEF patient with an LVEF ≤ 45% is prescribing against guideline, and the cardiologist should be alerted.
- BiPAP-ST for centrally predominant HF-related apnea where CPAP fails. Devices like the ResMed AirCurve ST, Lumis VPAP ST, or Philips DreamStation BiPAP Auto with ST capability are appropriate. Price range ₹1.4–2.2 lakh.
Multidisciplinary coordination
Heart failure patients with sleep-disordered breathing are best managed with a three-way coordination between cardiology, sleep medicine, and a home-respiratory service. In practice, this three-way loop exists at a handful of Indian tertiary centres and is absent at most. The consequence is that many patients get either sub-optimal cardiology management (because their OSA is driving the heart failure) or sub-optimal sleep management (because their HF decompensation is driving their apnea). A patient or family managing this should ask each specialist to actively loop in the other.
At the patient end, expect:
- Overnight pulse oximetry or home sleep study as initial screening.
- In-lab polysomnography for confirmation and titration — particularly important for HF patients where the mode decision is not just CPAP-or-not but also CPAP-versus-BiPAP-ST.
- Titration with CO₂ monitoring for BiPAP-ST initiations.
- Follow-up at 4 weeks and 3 months minimum, with cloud-downloaded usage and event data reviewed jointly with the cardiologist.
The bottom line
Sleep-disordered breathing in heart failure is common, clinically significant, and treatable — but the “treatable” depends on matching the mode to the phenotype and to the LVEF. CPAP works for obstructive predominant pictures regardless of LVEF. ASV is contraindicated in HFrEF with LVEF ≤ 45%. BiPAP-ST has a place in selected patients with central predominance and CPAP failure, under specialist care. Optimising heart failure medical therapy is always the starting point, and sleep-disordered breathing usually improves along with it.
Consult your cardiologist and a sleep physician before initiating positive-pressure therapy in heart failure. This article is educational and not a substitute for individual clinical decision-making.
References: SERVE-HF primary paper and subsequent regulatory action; CANPAP; Kaneko et al; Sasayama et al; current AHA and ESC heart failure guidelines on sleep-disordered breathing; AASM practice parameters on positive-pressure therapy in HF [CITATION].